register

News & Trends - Pharmaceuticals

Affordable medicines for over 500,000 Australians

Health Industry Hub | October 2, 2019 |
[Total: 1    Average: 5/5]

New PBS listings and price reductions enhance access to medicines for more than 500,000 Australian patients from October 1, 2019.

Treatments to treat lung cancer, lymphoblastic and acute leukaemia, and nausea associated with chemotherapy will now be available to patients on the PBS for $40.30 per script, or $6.50 with a concession card.

Prime Minister Scott Morrison said the Coalition would continue to list medicine on the PBS as quickly as possible.

“Our strong budget management means we can give Australian patients with access to life-saving and life-changing medicines quicker than ever before, without raising taxes,” the Prime Minister said. 

“This stands in stark contrast to Labor whose failed budget management drove the budget into deep deficit, forcing them to stop listing lifesaving and life changing medicines.”

The new or extending PBS listings from 1 October include:

  • Tecentriq and Avastin, will be extended on the PBS to include first line treatment of patients with stage IV metastatic non-squamous non-small cell lung cancer. Without PBS subsidy it would cost patients more than $11,400 per script (around 16 scripts per course of treatment); or more than $189,100 per course of treatment. An average of 755 patients per year (for six years) could benefit from this listing.
  • Besponsa, will be extended on the PBS to include patients with relapsed or refractory Philadelphia chromosome positive B-ALL. Without PBS subsidy, patients would pay more than $44,500 per script (around 3 scripts per course of treatment); or more than $122,900 per course of treatment without subsidised access through the PBS. An average of 16 patients per year (for six years) could benefit from this listing.
  • Blincyto, will be extended on the PBS to include patients with relapsed or refractory Philadelphia chromosome positive B-ALL. Without PBS subsidy, patients would pay more than more than $74,900 per script (around 2 scripts per course of treatment); or more than $122,900 per course of treatment. An average of 16 patients per year (for six years) could benefit from this listing.
  • Aprepitant, will be made available through the PBS for the treatment of patients with Nausea and vomiting associated with chemotherapy. Without PBS subsidy, patients would pay more than $80 per script (around 1 script per course of treatment). In 2018, 7,269 patients accessed a comparable treatment for this condition.

A customer experience mindset gives healthcare service providers and suppliers a healthy edge.
Enhance visibility and amplify your brand value proposition to our subscribers. Health Industry Hub offers a wealth of content in a one-stop-hub to connect and engage Pharma, MedTech and Biotech industry professionals. Contact us.

Minister for Health Greg Hunt said every six months, prices on a range of PBS medicines are also reduced as a result of the Morrison Government’s Price Disclosure Policy.

Fifteen common medicines – sold as 175 medicine brands will be cheaper for general (non-concessional) patients, and these include:

  • Pregabalin: around 208,000 patients per year who have seizures or nerve pain will now pay $28.27 per script for 75 mg capsules, a saving of up to $5.11 per script
  • Ezetimibe: around 60,000 patients per year with high cholesterol levels will now pay $33.86 per script for 10 mg tablets, a saving of up to $6.44 per script
  • Ezetimibe with Simvastatin: about 245,000 patients with high cholesterol levels will now pay $37.77 per script for 10 mg tablets, a saving of up to $2.53 per script.

You may also like An Australian first treatment combo PBS listed in lung cancer


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Medical

Medical Pharma Biotech MedTech - Clinical changes to cervical cancer screening program

Clinical changes to cervical cancer screening program

Health Industry Hub | March 5, 2021 |

Medical News: Changes to the National Cervical Screening Program (NCSP) Guidelines for the clinical management of women at intermediate risk […]

More


News & Trends - Medical Technology

MedTech News - Philips partners for world-first research to reduce patient anxiety during MRI scans

Philips partners for world-first research to reduce patient anxiety during MRI scans

Health Industry Hub | March 5, 2021 |

MedTech News: Philips, a global leader in health technology, is teaming up to test the effects of custom-made animation within […]

More


News & Trends - Pharmaceuticals

Pharma News - Merck marks International Women’s Day with commitment to gender equality and APEC research prize

Merck marks International Women’s Day with commitment to gender equality and APEC research prize

Health Industry Hub | March 5, 2021 |

Pharma News: Merck, a leading science and technology company, is marking International Women’s Day (8 March) with a range of […]

More


News & Trends - Medical Technology

MedTech News - Health insurers holding $1.8 billion excess funds from deferred claims

Health insurers holding $1.8 billion excess funds from deferred claims

Health Industry Hub | March 5, 2021 |

MedTech News: The Australian Private Hospitals Association (APHA) has welcomed the move by private health insurer HBF to repay members […]

More